P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil

Cronemberger, Eduardo; Baldotto, Clarissa; Marinho, Felipe Da Silva; Marchi, Pedro De; Araujo, Luiz H.; Franke, F.; Salles, Paulo Guilherme de Oliveira; Calabrich, Aknar; Almeida, Teresa; Custodio, M.; Araujo, Carla; Horacio, M.; Castro, Gilberto de

doi:10.1016/j.jtho.2018.08.1572

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interim analysis of this trial has been presented in WCLC 2018, in a poster section as follows: P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil ( 6 ).…”

Section: Methodsmentioning

confidence: 99%

“…Hospital de Caridade Ijuí n. 1.959.243; Instituto Nacional do Câncer José Alencar n. 2.169.046; Sociedade Pernambucana de Combate ao Câncer n. 1.975.285; Associac¸ão Mario Penna n. 2.255.393. The study procedures were initiated only after the final ethical approval.An interim analysis of this trial has been presented in WCLC 2018, in a poster section as follows: P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil(6).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC

Cronemberger¹,

Baldotto

Marinho

et al. 2020

Clinics

View full text Add to dashboard Cite

To evaluate the molecular testing and treatment patterns in a retrospective cohort of newly diagnosed treatment-naïve patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: This is an observational retrospective cohort study conducted across 10 cancer centers in Brazil. Treatment-naïve patients with locally advanced or metastatic NSCLC were enrolled from January to December 2014. The following data were collected from the medical records of patients from diagnosis until the last record (death, loss to follow-up, or the end of the maximum follow-up period): demographics; medical history; smoking status; disease characteristics; previous treatments; and molecular testing patterns and results. The overall survival (OS) was also estimated. Results: A total of 391 patients from 8 different Brazilian states were included, with a median age of 64.1 years (23.7-98.7), with most patients being males (60.1%). The smoking status of 74.2% of patients was a 'former' or 'current smoker'. Stage IV NSCLC at diagnosis was observed in 82.4% of patients, with 269 of them (68.8%) presenting adenocarcinoma (ADC). Among the stage IV ADC patients, 54.0% were referred for molecular testing. Among the patients with an available epidermal growth factor receptor (EGFR) mutation status, 31 (24.0%) were EGFR-positive. The first-line treatment was a platinum-based chemotherapy for 98 patients (25.1%), while nonplatinum-based regimens were used in 54 patients (13.8%). OS data were available for 370 patients, with a median OS of 10.8 months. Never smokers had a significantly higher median OS versus current or former smokers (14.6 versus 9.1 months; log-rank p=0.003). Among the patients for whom molecular testing data were available, those with EGFR-positive results had a longer median OS (34.6 versus 12.8 months; log-rank p=0.003). Conclusion: Our findings provide relevant information for prescribers and policy decision-makers by highlighting the unmet needs of patients and the importance of molecular testing in newly diagnosed locally advanced or metastatic lung adenocarcinoma. We also highlight the respective EGFR-tyrosine kinase inhibitor treatment when the result is positive and the areas in which further efforts are required to grant access to effective treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC

Cronemberger¹,

Baldotto

Marinho

et al. 2020

Clinics

View full text Add to dashboard Cite

show abstract

“…Data regarding ALK rearrangements and PD-L1 expression are scarce. All of that has direct impacts on overall survival rates, which differ between patients treated in the public sector and those treated in the private sector, 12 the median overall survival among patients with stage IV adenocarcinoma being 14.2 months for those who underwent molecular testing compared with 8.5 months for those who did not.…”

mentioning

confidence: 99%